Lithea secures Vinnova grant to advance international funding application
Lithea has been awarded a SEK 300,000 planning grant from Vinnova under the call Planning Grant for International Proposal 2025, part of the Global Cooperation – Special Initiatives program. The grant supports Swedish organizations in developing competitive applications for international research and innovation calls.
With this funding, Lithea will prepare a proposal for an international call to the EIC Accelerator Open, focusing on its intratumoral drug delivery platform for oncology. The planning project will include strategic refinement of the scientific concept, technical validation, and business case development to ensure the proposal meets international standards.
“This grant from Vinnova is a strong endorsement of our innovation strategy and international ambitions. It enables us to invest in the groundwork needed to bring our cancer therapy platform to a global stage,” said Ludvig Sjöberg, CEO at Lithea.
The EIC Accelerator Open is a European funding program that supports high-risk, high-impact innovations from startups and SMEs across all sectors. It offers up to €2.5 million in grants and up to €10 million in equity investments to help companies scale breakthrough technologies. Lithea aims to submit a proposal to this program as part of its internationalization strategy supported by the Vinnova planning grant.
LIT1001 is an innovative drug product designed for local delivery of doxorubicin, a widely used chemotherapeutic agent. Utilizing Lithea’s proprietary bone mineral-based technology platform comprising Calcium Sulfate and Hydroxyapatite, LIT1001 enables sustained and controlled release of doxorubicin directly at the tumor site, minimizing systemic toxicity while enhancing local efficacy.
Lithea is a pharmatech company based in Lund, Sweden, focused on the development of advanced therapies for solid tumor, and with the mission to prolong the lives of cancer patients. For more information, please visit www.lithea-pharma.com.
Ludvig Sjöberg, CEO
ludvig.sjoberg@lithea-pharma.com
October 13, 2025
Lund, Sweden
Download pressrelease: Pressrelease Lithea Vinnova 2025-10-13.pdf